Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice TargetHot
Scotiabank analyst Louise Chen maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Outperform and raises the price target from $558 to $660.
Scotiabank analyst Louise Chen maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Outperform and raises the price target from $558 to $660.